FZD7 and cancer: Considering the recent success of radionuclide therapy for the treatment of FZD10 overexpressing cancers at preclinical level, namely synovial sarcoma, it is plausible that other types of cancer overexpressing different isoforms of the frizzled receptor (e.g., FZD7) would benefit from an analogous approach.